Role of insulin-like growth factor binding proteins in mammary gland development

Journal of Mammary Gland Biology and Neoplasia

Volumn 13, Issue 4, 2008, Pages 443-453

  Flint, David J ^a   Tonner, E ^a   Beattie, J ^b   Allan, G J ^a  

^a UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^b UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

Apoptosis; Extracellular matrix; Proteolysis, CCN, TIC; Transgenic

Indexed keywords

CCAAT ENHANCER BINDING PROTEIN BETA; GROWTH HORMONE; MESSENGER RNA; PROLACTIN; SOMATOMEDIN; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN BINDING PROTEIN 2; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN BINDING PROTEIN 4; SOMATOMEDIN BINDING PROTEIN 5;

BREAST DEVELOPMENT; DOWNSTREAM PROCESSING; EMBRYO DEVELOPMENT; EXTRACELLULAR MATRIX; GENE FUNCTION; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; INVOLUTION; LACTATION; MAMMARY GLAND; MAMMARY GLAND FUNCTION; MORPHOGENESIS; NONHUMAN; PREGNANCY; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE; PROTEIN SYNTHESIS; PUBERTY; REVIEW; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION;

ANIMALS; CELL SURVIVAL; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; MAMMARY GLANDS, ANIMAL; MAMMARY GLANDS, HUMAN; MODELS, BIOLOGICAL; PROLACTIN;

EID: 57149126070     PISSN: 10833021     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10911-008-9095-3     Document Type: Review

References (106)

1. Tonner E, Allan GJ, Flint DJ. Hormonal control of plasmin and tissue-type plasminogen activator activity in rat milk during involution of the mammary gland. J Endocrinol. 2000;167(2):265-73.
2. Wood TL, Richert MM, Stull MA, Allar MA. The insulin-like growth factors (IGFs) and IGF binding proteins in postnatal development of murine mammary glands. J Mammary Gland Biol Neoplasia. 2000;5(1):31-42.
3. Ruan W, Catanese V, Wieczorek R, Feldman M, Kleinberg DL. Estradiol enhances the stimulatory effect of insulin-like growth factor-I (IGF-I) on mammary development and growth hormone-induced IGF-I messenger ribonucleic acid. Endocrinology 1995;136(3):1296-302.
4. Kleinberg DL. Early mammary development: Growth hormone and IGF-1. J Mammary Gland Biol Neoplasia. 1997;2(1):49-57.
5. Weber MS, Boyle PL, Corl BA, Wong EA, Gwazdauskas FC, Akers RM. Expression of ovine insulin-like growth factor-1 (IGF-1) stimulates alveolar bud development in mammary glands of transgenic mice. Endocrine 1998;8(3):251-9.
6. Bates P, Fisher R, Ward A, Richardson L, Hill DJ, Graham CF. Mammary cancer in transgenic mice expressing insulin-like growth factor II (IGF-II). Br J Cancer. 1995;72(5):1189-93.
7. Flint DJ, Boutinaud M, Tonner E, Wilde CJ, Hurley W, Accorsi PA, et al. Insulin-like growth factor binding proteins initiate cell death and extracellular matrix remodeling in the mammary gland. Domest Anim Endocrinol. 2005;29(2):274-82.
8. Neuenschwander S, Schwartz A, Wood TL, Roberts CT Jr., Henninghausen L, LeRoith D. Involution of the lactating mammary gland is inhibited by the IGF system in a transgenic mouse model. J Clin Invest. 1996;97(10):2225-32.
9. Hadsell DL, Greenberg NM, Fligger JM, Baumrucker CR, Rosen JM. Targeted expression of des(1-3) human insulin-like growth factor I in transgenic mice influences mammary gland development and IGF-binding protein expression. Endocrinology 1996;137(1):321-30.
10. Kleinberg DL, Feldman M, Ruan W. IGF-I: An essential factor in terminal end bud formation and ductal morphogenesis. J Mammary Gland Biol Neoplasia. 2000;5(1):7-17.
11. Arai T, Parker A, Busby W Jr., Clemmons DR. Heparin, heparan sulfate, and dermatan sulfate regulate formation of the insulin-like growth factor-I and insulin-like growth factor-binding protein complexes. J Biol Chem. 1994;269(32):20388-93.
12. Mohan S, Nakao Y, Honda Y, Landale E, Leser U, Dony C, et al. Studies on the mechanisms by which insulin-like growth factor (IGF) binding protein-4 (IGFBP-4) and IGFBP-5 modulate IGF actions in bone cells. J Biol Chem. 1995;270(35):20424-31.
13. Flint DJ, Tonner E, Allan GJ. Insulin-like growth factor binding proteins: IGF-dependent and -independent effects in the mammary gland. J Mammary Gland Biol Neoplasia. 2000;5(1):65-73.
14. Allar MA, Wood TL. Expression of the insulin-like growth factor binding proteins during postnatal development of the murine mammary gland. Endocrinology 2004;145(5):2467-77.
15. Humphreys RC. Programmed cell death in the terminal endbud. J Mammary Gland Biol Neoplasia. 1999;4(2):213-20.
16. Blatchford DR, Quarrie LH, Tonner E, McCarthy C, Flint DJ, Wilde CJ. Influence of microenvironment on mammary epithelial cell survival in primary culture. J Cell Physiol. 1999;181(2):304-11.
17. Gouon-Evans V, Rothenberg ME, Pollard JW. Postnatal mammary gland development requires macrophages and eosinophils. Development 2000;127(11):2269-82.
18. Tonner E, Barber MC, Travers MT, Logan A, Flint DJ. Hormonal control of insulin-like growth factor-binding protein-5 production in the involuting mammary gland of the rat. Endocrinology 1997;138(12):5101-7.
19. Rosfjord EC, Dickson RB. Growth factors, apoptosis, and survival of mammary epithelial cells. J Mammary Gland Biol Neoplasia. 1999;4(2):229-37.
20. Theil PK, Labouriau R, Sejrsen K, Thomsen B, Sorensen MT. Expression of genes involved in regulation of cell turnover during milk stasis and lactation rescue in sow mammary glands. J Anim Sci. 2005;83(10):2349-56.
21. Norgaard JV, Theil PK, Sorensen MT, Sejrsen K. Cellular mechanisms in regulating mammary cell turnover during lactation and dry period in dairy cows. J Dairy Sci. 2008;91(6):2319-27.
22. Brisken C, Ayyannan A, Nguyen C, Heineman A, Reinhardt F, Tan J, et al. IGF-2 is a mediator of prolactin-induced morphogenesis in the breast. Dev Cell. 2002;3(6):877-87.
23. Hovey RC, Harris J, Hadsell DL, Lee AV, Ormandy CJ, Vonderhaar BK. Local insulin-like growth factor-II mediates prolactin-induced mammary gland development. Mol Endocrinol. 2003;17(3):460-71.
24. Grimm SL, Seagroves TN, Kabotyanski EB, Hovey RC, Vonderhaar BK, Lydon JP, et al. Disruption of steroid and prolactin receptor patterning in the mammary gland correlates with a block in lobuloalveolar development. Mol Endocrinol. 2002;16(12):2675-91.
25. Marshman E, Green KA, Flint DJ, White A, Streuli CH, Westwood M. Insulin-like growth factor binding protein 5 and apoptosis in mammary epithelial cells. J Cell Sci. 2003;116(Pt 4):675-82.
26. Allan GJ, Tonner E, Barber MC, Travers MT, Shand JH, Vernon RG, et al. Growth hormone, acting in part through the insulin-like growth factor axis, rescues developmental, but not metabolic, activity in the mammary gland of mice expressing a single allele of the prolactin receptor. Endocrinology 2002;143(11):4310-9.
27. Tonner E, Barber MC, Allan GJ, Beattie J, Webster J, Whitelaw CB, et al. Insulin-like growth factor binding protein-5 (IGFBP-5) induces premature cell death in the mammary glands of transgenic mice. Development 2002;129(19):4547-57.
28. Ning Y, Hoang B, Schuller AG, Cominski TP, Hsu MS, Wood TL, et al. Delayed mammary gland involution in mice with mutation of the insulin-like growth factor binding protein 5 gene. Endocrinology 2007;148(5):2138-47.
29. Silha JV, Murphy LJ. Insulin-like growth factor binding proteins in development. Adv Exp Med Biol. 2005;567:55-89.
30. Pell JM, Salih DA, Cobb LJ, Tripathi G, Drozd A. The role of insulin-like growth factor binding proteins in development. Rev Endocr Metab Disord. 2005;6(3):189-98.
31. Rotwein P, James PL, Kou K. Rapid activation of insulin-like growth factor binding protein-5 gene transcription during myoblast differentiation. Mol Endocrinol. 1995;9(7):913-23.
32. Allan GJ, Flint DJ, Patel K. Insulin-like growth factor axis during embryonic development. Reproduction 2001;122(1):31-9.
33. Allander SV, Coleman M, Luthman H, Powell DR. Chicken insulin-like growth factor binding protein (IGFBP)-5: Conservation of IGFBP-5 structure and expression during evolution. Comp Biochem Physiol B Biochem Mol Biol. 1997;116(4):477-83.
34. Krumlauf R. Hox genes in vertebrate development. Cell 1994;78(2):191-201.
35. Ning Y, Schuller AG, Bradshaw S, Rotwein P, Ludwig T, Frystyk J, et al. Diminished growth and enhanced glucose metabolism in triple knockout mice containing mutations of insulin-like growth factor binding protein-3, -4, and -5. Mol Endocrinol. 2006;20(9):2173-86.
36. Murali SG, Liu X, Nelson DW, Hull AK, Grahn M, Clayton MK, et al. Intestinotrophic effects of exogenous IGF-I are not diminished in IGF binding protein-5 knockout mice. Am J Physiol Regul Integr Comp Physiol. 2007;292(6):R2144-50.
37. Ning Y, Schuller AG, Conover CA, Pintar JE. Insulin-like growth factor (IGF) binding protein-4 is both a positive and negative regulator of IGF activity in vivo. Mol Endocrinol. 2008;22(5):1213-25.
38. Leu JI, Crissey MA, Craig LE, Taub R. Impaired hepatocyte DNA synthetic response posthepatectomy in insulin-like growth factor binding protein 1-deficient mice with defects in C/EBP beta and mitogen-activated protein kinase/extracellular signal-regulated kinase regulation. Mol Cell Biol. 2003;23(4):1251-9.
39. DeMambro VE, Clemmons DR, Horton LG, Bouxsein ML, Wood TL, Beamer WG, et al. Gender-specific changes in bone turnover and skeletal architecture in igfbp-2-null mice. Endocrinology 2008;149(5):2051-61.
40. Silha JV, Murphy LJ. Insights from insulin-like growth factor binding protein transgenic mice. Endocrinology 2002;143(10):3711-4.
41. Wolf E, Schneider MR, Zhou R, Fisch TM, Herbach N, Dahlhoff M, et al. Functional consequences of IGFBP excess-lessons from transgenic mice. Pediatr Nephrol. 2005;20(3):269-78.
42. Rajkumar K, Barron D, Lewitt MS, Murphy LJ. Growth retardation and hyperglycemia in insulin-like growth factor binding protein-1 transgenic mice. Endocrinology 1995;136(9):4029-34.
43. Rajkumar K, Murphy LJ. Enhanced gluconeogenesis and hepatic insulin resistance in insulin-like growth factor binding protein-1 transgenic mice. Biochim Biophys Acta. 1999;1426(3):491-7.
44. Gay E, Seurin D, Babajko S, Doublier S, Cazillis M, Binoux M. Liver-specific expression of human insulin-like growth factor binding protein-1 in transgenic mice: Repercussions on reproduction, ante- and perinatal mortality and postnatal growth. Endocrinology 1997;138(7):2937-47.
45. Hoeflich A, Fettscher O, Lahm H, Blum WF, Kolb HJ, Engelhardt D, et al. Overexpression of insulin-like growth factor-binding protein-2 results in increased tumorigenic potential in Y-1 adrenocortical tumor cells. Cancer Res. 2000;60(4):834-8.
46. Silha JV, Sheppard PC, Mishra S, Gui Y, Schwartz J, Dodd JG, et al. Insulin-like growth factor (IGF) binding protein-3 attenuates prostate tumor growth by IGF-dependent and IGF-independent mechanisms. Endocrinology 2006;147(5):2112-21.
47. Silha JV, Gui Y, Mishra S, Leckstrom A, Cohen P, Murphy LJ. Overexpression of gly56/gly80/gly81-mutant insulin-like growth factor-binding protein-3 in transgenic mice. Endocrinology 2005;146(3):1523-31.
48. Zhang M, Smith EP, Kuroda H, Banach W, Chernausek SD, Fagin JA. Targeted expression of a protease-resistant IGFBP-4 mutant in smooth muscle of transgenic mice results in IGFBP-4 stabilization and smooth muscle hypotrophy. J Biol Chem. 2002;277(24):21285-90.
49. Zhou R, Flaswinkel H, Schneider MR, Lahm H, Hoeflich A, Wanke R, et al. Insulin-like growth factor-binding protein-4 inhibits growth of the thymus in transgenic mice. J Mol Endocrinol. 2004;32(2):349-64.
50. Salih DA, Tripathi G, Holding C, Szestak TA, Gonzalez MI, Carter EJ, et al. Insulin-like growth factor-binding protein 5 (Igfbp5) compromises survival, growth, muscle development, and fertility in mice. Proc Natl Acad Sci USA. 2004;101(12):4314-9.
51. Salih DA, Mohan S, Kasukawa Y, Tripathi G, Lovett FA, Anderson NF, et al. Insulin-like growth factor-binding protein-5 induces a gender-related decrease in bone mineral density in transgenic mice. Endocrinology 2005;146(2):931-40.
52. Bienvenu G, Seurin D, Grellier P, Froment P, Baudrimont M, Monget P, et al. Insulin-like growth factor binding protein-6 transgenic mice: postnatal growth, brain development, and reproduction abnormalities. Endocrinology 2004;145(5):2412-20.
53. Bunn RC, Fowlkes JL. Insulin-like growth factor binding protein proteolysis. Trends Endocrinol Metab. 2003;14(4):176-81.
54. Imai Y, Busby WH Jr., Smith CE, Clarke JB, Garmong AJ, Horwitz GD, et al. Protease-resistant form of insulin-like growth factor-binding protein 5 is an inhibitor of insulin-like growth factor-I actions on porcine smooth muscle cells in culture. J Clin Invest. 1997;100(10):2596-605.
55. Kajantie E, Dunkel L, Rutanen EM, Seppala M, Koistinen R, Sarnesto A, et al. IGF-I, IGF binding protein (IGFBP)-3, phosphoisoforms of IGFBP-1, and postnatal growth in very low birth weight infants. J Clin Endocrinol Metab. 2002;87(5):2171-9.
56. Jones JI, Gockerman A, Busby WH Jr, Wright G, Clemmons DR. Insulin-like growth factor binding protein 1 stimulates cell migration and binds to the alpha 5 beta 1 integrin by means of its Arg-Gly-Asp sequence. Proc Natl Acad Sci USA. 1993;90(22):10553-7.
57. Schedlich LJ, Le Page SL, Firth SM, Briggs LJ, Jans DA, Baxter RC. Nuclear import of insulin-like growth factor-binding protein-3 and -5 is mediated by the importin beta subunit. J Biol Chem. 2000;275(31):23462-70.
58. Amaar YG, Thompson GR, Linkhart TA, Chen ST, Baylink DJ, Mohan S. Insulin-like growth factor-binding protein 5 (IGFBP-5) interacts with a four and a half LIM protein 2 (FHL2). J Biol Chem. 2002;277(14):12053-60.
59. Xu Q, Li S, Zhao Y, Maures TJ, Yin P, Duan C. Evidence that IGF binding protein-5 functions as a ligand-independent transcriptional regulator in vascular smooth muscle cells. Circ Res. 2004;94(5):E46-54.
60. Jurgeit A, Berlato C, Obrist P, Ploner C, Massoner P, Schmolzer J, et al. Insulin-like growth factor-binding protein-5 enters vesicular structures but not the nucleus. Traffic 2007;8(12):1815-28.
61. Amaar YG, Baylink DJ, Mohan S. Ras-association domain family 1 protein, RASSF1C, is an IGFBP-5 binding partner and a potential regulator of osteoblast cell proliferation. J Bone Miner Res. 2005;20(8):1430-9.
62. Leal SM, Liu Q, Huang SS, Huang JS. The type V transforming growth factor beta receptor is the putative insulin-like growth factor-binding protein 3 receptor. J Biol Chem. 1997;272(33):20572-6.
63. Andress DL. Insulin-like growth factor-binding protein-5 (IGFBP-5) stimulates phosphorylation of the IGFBP-5 receptor. Am J Physiol. 1998;274(4 Pt 1):E744-50.
64. Oh Y, Gucev Z, Ng L, Muller HL, Rosenfeld RG. Antiproliferative actions of insulin-like growth factor binding protein (IGFBP)-3 in human breast cancer cells. Prog Growth Factor Res. 1995;6(2-4):503-12.
65. Rajah R, Valentinis B, Cohen P. Insulin-like growth factor (IGF)-binding protein-3 induces apoptosis and mediates the effects of transforming growth factor-beta1 on programmed cell death through a p53- and IGF-independent mechanism. J Biol Chem. 1997;272(18):12181-8.
66. Oh Y, Muller HL, Ng L, Rosenfeld RG. Transforming growth factor-beta-induced cell growth inhibition in human breast cancer cells is mediated through insulin-like growth factor binding protein-3 action. J Biol Chem. 1995;270:13589-92.
67. Leal SM, Huang SS, Huang JS. Interactions of high affinity insulin-like growth factor-binding proteins with the type V transforming growth factor-beta receptor in mink lung epithelial cells. J Biol Chem. 1999;274(10):6711-7.
68. McCaig C, Perks CM, Holly JM. Intrinsic actions of IGFBP-3 and IGFBP-5 on Hs578T breast cancer epithelial cells: Inhibition or accentuation of attachment and survival is dependent upon the presence of fibronectin. J Cell Sci. 2002;115(Pt 22):4293-303.
69. Lee KW, Liu B, Ma L, Li H, Bang P, Koeffler HP, et al. Cellular internalization of insulin-like growth factor binding protein-3: distinct endocytic pathways facilitate re-uptake and nuclear localization. J Biol Chem. 2004;279(1):469-76.
70. Beattie J, Allan GJ, Lochrie JD, Flint DJ. Insulin-like growth factor-binding protein-5 (IGFBP-5): A critical member of the IGF axis. Biochem J. 2006;395(1):1-19.
71. Clemmons DR. Role of insulin-like growth factor binding proteins in controlling IGF actions. Mol Cell Endocrinol. 1998;140(1-2):19-24.
72. Pilewski JM, Liu L, Henry AC, Knauer AV, Feghali-Bostwick CA. Insulin-like growth factor binding proteins 3 and 5 are overexpressed in idiopathic pulmonary fibrosis and contribute to extracellular matrix deposition. Am J Pathol. 2005;166(2):399-407.
73. Jones JI, Gockerman A, Busby WH Jr., Camacho-Hubner C, Clemmons DR. Extracellular matrix contains insulin-like growth factor binding protein-5: Potentiation of the effects of IGF-I. J Cell Biol. 1993;121(3):679-87.
74. Liu B, Weinzimer SA, Gibson TB, Mascarenhas D, Cohen P. Type I alpha collagen is an IGFBP-3 binding protein. Growth Horm IGF Res. 2003;13(2-3):89-97.
75. Nam TJ, Busby WH Jr., Clemmons DR. Human fibroblasts secrete a serine protease that cleaves insulin-like growth factor-binding protein-5. Endocrinology 1994;135(4):1385-91.
76. Morales TI. The role and content of endogenous insulin-like growth factor-binding proteins in bovine articular cartilage. Arch Biochem Biophys. 1997;343(2):164-72.
77. Firth SM, Baxter RC. The role of glycosylation in the action of IGFBP-3. Prog Growth Factor Res. 1995;6(2-4):223-9.
78. Sorrell AM, Shand JH, Tonner E, Gamberoni M, Accorsi PA, Beattie J, et al. Insulin-like growth factor-binding protein-5 activates plasminogen by interaction with tissue plasminogen activator, independently of its ability to bind to plasminogen activator inhibitor-1, insulin-like growth factor-I, or heparin. J Biol Chem. 2006;281(16):10883-9.
79. Inoki I, Shiomi T, Hashimoto G, Enomoto H, Nakamura H, Makino K, et al. Connective tissue growth factor binds vascular endothelial growth factor (VEGF) and inhibits VEGF-induced angiogenesis. FASEB J. 2002;16(2):219-21.
80. Abreu JG, Ketpura NI, Reversade B, De Robertis EM. Connective-tissue growth factor (CTGF) modulates cell signalling by BMP and TGF-beta. Nat Cell Biol. 2002;4(8):599-604.
81. Nguyen TQ, Goldschmeding R. Bone morphogenetic protein-7 and connective tissue growth factor: Novel targets for treatment of renal fibrosis? Pharm Res. 2008;25:2416-26.
82. Honegger B, Galic M, Kohler K, Wittwer F, Brogiolo W, Hafen E, et al. Imp-L2, a putative homolog of vertebrate IGF-binding protein 7, counteracts insulin signaling in Drosophila and is essential for starvation resistance. J Biol. 2008;7(3):10.
83. Alic N, Partridge L. Stage debut for the elusive Drosophila insulin-like growth factor binding protein. J Biol. 2008;7(6):18.
84. Nam TJ, Busby WH Jr., Rees C, Clemmons DR. Thrombospondin and osteopontin bind to insulin-like growth factor (IGF)-binding protein-5 leading to an alteration in IGF-I-stimulated cell growth. Endocrinology 2000;141(3):1100-6.
85. Clemmons DR, Busby WH, Arai T, Nam TJ, Clarke JB, Jones JI, et al. Role of insulin-like growth factor binding proteins in the control of IGF actions. Prog Growth Factor Res. 1995;6(2-4):357-66.
86. Hampel B, Fortschegger K, Ressler S, Chang MW, Unterluggauer H, Breitwieser A, et al. Increased expression of extracellular proteins as a hallmark of human endothelial cell in vitro senescence. Exp Gerontol. 2006;41(5):474-81.
87. Yoon IK, Kim HK, Kim YK, Song IH, Kim W, Kim S, et al. Exploration of replicative senescence-associated genes in human dermal fibroblasts by cDNA microarray technology. Exp Gerontol. 2004;39(9):1369-78.
88. Kim KS, Seu YB, Baek SH, Kim MJ, Kim KJ, Kim JH, et al. Induction of cellular senescence by insulin-like growth factor binding protein-5 through a p53-dependent mechanism. Mol Biol Cell. 2007;18(11):4543-52.
89. Beausejour CM, Krtolica A, Galimi F, Narita M, Lowe SW, Yaswen P, et al. Reversal of human cellular senescence: Roles of the p53 and p16 pathways. EMBO J. 2003;22(16):4212-22.
90. Campisi J. Senescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors. Cell 2005;120(4):513-22.
91. Kenyon C. A conserved regulatory system for aging. Cell 2001;105(2):165-8.
92. Longo VD, Finch CE. Evolutionary medicine: From dwarf model systems to healthy centenarians? Science 2003;299(5611):1342-6.
93. Chakravarthy MV, Abraha TW, Schwartz RJ, Fiorotto ML, Booth FW. Insulin-like growth factor-I extends in vitro replicative life span of skeletal muscle satellite cells by enhancing G1/S cell cycle progression via the activation of phosphatidylinositol 3′-kinase/Akt signaling pathway. J Biol Chem. 2000;275(46):35942-52.
94. Shimokawa I, Higami Y, Tsuchiya T, Otani H, Komatsu T, Chiba T, et al. Life span extension by reduction of the growth hormone-insulin-like growth factor-1 axis: Relation to caloric restriction. FASEB J. 2003;17(9):1108-9.
95. Shimokawa I, Higami Y, Utsuyama M, Tuchiya T, Komatsu T, Chiba T, et al. Life span extension by reduction in growth hormone-insulin-like growth factor-1 axis in a transgenic rat model. Am J Pathol. 2002;160(6):2259-65.
96. Holzenberger M. The GH/IGF-I axis and longevity. Eur J Endocrinol. 2004;151(Suppl 1):S23-27.
97. Holzenberger M, Dupont J, Ducos B, Leneuve P, Geloen A, Even PC, et al. IGF-1 receptor regulates lifespan and resistance to oxidative stress in mice. Nature 2003;421(6919):182-7.
98. Giudice LC, Irwin JC, Dsupin BA, Pannier EM, Jin IH, Vu TH, et al. Insulin-like growth factor (IGF), IGF binding protein (IGFBP), and IGF receptor gene expression and IGFBP synthesis in human uterine leiomyomata. Hum Reprod. 1993;8(11):1796-806.
99. Hossenlopp P, Segovia B, Lassarre C, Roghani M, Bredon M, Binoux M. Evidence of enzymatic degradation of insulin-like growth factor-binding proteins in the 150 K complex during pregnancy. J Clin Endocrinol Metab. 1990;71(4):797-805.
100. Davenport ML, Clemmons DR, Miles MV, Camacho-Hubner C, D'Ercole AJ, Underwood LE. Regulation of serum insulin-like growth factor-I (IGF-I) and IGF binding proteins during rat pregnancy. Endocrinology 1990;127(3):1278-86.
101. Fielder PJ, Thordarson G, English A, Rosenfeld RG, Talamantes F. Expression of a lactogen-dependent insulin-like growth factor-binding protein in cultured mouse mammary epithelial cells. Endocrinology 1992;131(1):261-7.
102. Claussen M, Zapf J, Braulke T. Proteolysis of insulin-like growth factor binding protein-5 by pregnancy serum and amniotic fluid. Endocrinology 1994;134(4):1964-6.
103. Lee KO, Oh Y, Giudice LC, Cohen P, Peehl DM, Rosenfeld RG. Identification of insulin-like growth factor-binding protein-3 (IGFBP-3) fragments and IGFBP-5 proteolytic activity in human seminal plasma: A comparison of normal and vasectomized patients. J Clin Endocrinol Metab. 1994;79(5):1367-72.
104. Xu S, Cwyfan-Hughes SC, van der Stappen JW, Sansom J, Burton JL, Donnelly M, et al. Altered insulin-like growth factor-II (IGF-II) level and IGF-binding protein-3 (IGFBP-3) protease activity in interstitial fluid taken from the skin lesion of psoriasis. J Invest Dermatol. 1996;106(1):109-12.
105. Xu S, Savage P, Burton JL, Sansom J, Holly JM. Proteolysis of insulin-like growth factor-binding protein-3 by human skin keratinocytes in culture in comparison to that in skin interstitial fluid: The role and regulation of components of the plasmin system. J Clin Endocrinol Metab. 1997;82(6):1863-8.
106. Hadsell DL, Bonnette SG. IGF and insulin action in the mammary gland: lessons from transgenic and knockout models. J Mammary Gland Biol Neoplasia. 2000;5(1):19-30.